{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Ma B"],"pubmed_abstract":["Despite recent progress in treating advanced non-small cell lung cancer, clinical intervention in extensive-stage small-cell lung cancer (ES-SCLC) remains stagnant. The purpose of this study was to evaluate the clinical efficacy of cytokine-induced killer (CIK) cells combined with cytotoxic chemotherapy, followed by anti-programmed death 1 antibody (sintilimab) maintenance, in ES-SCLC patients. To explore a new method for safe treatment of ES-SCLC patients, thirteen ES-SCLC patients were enrolled between June 2019 and December 2021. All patients received first-line chemotherapy (etoposide plus platinum) combined with CIK cell therapy. Patients who reached a stable disease state or responded well to treatment received sintilimab maintenance treatment. The primary objective of this study was"],"journal":["Frontiers in oncology"],"pagination":["852885"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9507303"],"repository":["biostudies-literature"],"pubmed_title":["Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer."],"pmcid":["PMC9507303"],"pubmed_authors":["Zhou M","Zhang F","Fu X","Huang H","Li F","Zhou Y","Gao Q","Ma B","Yang Y","Zhao L","Guo J","Zhang Y","Xu B","Shang Y","Lin H","Wang Z"],"additional_accession":[]},"is_claimable":false,"name":"Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer.","description":"Despite recent progress in treating advanced non-small cell lung cancer, clinical intervention in extensive-stage small-cell lung cancer (ES-SCLC) remains stagnant. The purpose of this study was to evaluate the clinical efficacy of cytokine-induced killer (CIK) cells combined with cytotoxic chemotherapy, followed by anti-programmed death 1 antibody (sintilimab) maintenance, in ES-SCLC patients. To explore a new method for safe treatment of ES-SCLC patients, thirteen ES-SCLC patients were enrolled between June 2019 and December 2021. All patients received first-line chemotherapy (etoposide plus platinum) combined with CIK cell therapy. Patients who reached a stable disease state or responded well to treatment received sintilimab maintenance treatment. The primary objective of this study was","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-22T00:41:07.205Z","creation":"2025-04-05T19:37:41.127Z"},"accession":"S-EPMC9507303","cross_references":{"pubmed":["36158690"],"doi":["10.3389/fonc.2022.852885"]}}